Capricor Therapeutics (CAPR) shares fell about 12% on Tuesday after B. Riley and Roth Capital downgraded the stock to neutral from buy.
B. Riley cut its price target to $10 per share from $63, while Roth Capital lowered its target to $7 per share from $38.
Trading volume stood at over 11.5 million shares, compared with a daily average of more than 1.8 million.
Price: 6.18, Change: -0.81, Percent Change: -11.61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.